Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
73°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Equillium Inc
(NQ:
EQ
)
0.8550
-0.0050 (-0.58%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Equillium Inc
< Previous
1
2
3
Next >
Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists
May 09, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR
April 25, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology
April 04, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates
March 23, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation
March 23, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates
February 16, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Provides Timing Update on Conference Presentations
February 15, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference
February 09, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR
January 10, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
January 05, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis
January 04, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma
January 04, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab
December 13, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates
November 10, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at Two Upcoming Investor Conferences
November 09, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting
November 05, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology Meeting
November 05, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and Exposition
November 04, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus Patients Treated with Itolizumab in the EQUALISE Study Presented at the ACR Annual Meeting
November 02, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual Meeting
October 18, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021
September 30, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
September 22, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis
August 11, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update
August 10, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the BTIG Virtual Biotechnology Conference
August 05, 2021
From
Equillium, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.